The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer

BMC Cancer

Research Article

Dong-Young Noh¹  Yunhee Lee²  Hyuna Sung²  Ji-Yeob Choi³  Sue K Park⁴  Daehee Kang⁴  Kyoung-Mu Lee⁵  Sujee Jeon⁶  Sang-Ah Lee⁷  Keun-Young Yoo⁸  Sohee Han⁸  Minkyo Song⁸  Sei-Hyun Ahn⁹ 

[1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea;Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea;Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea;Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea;Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea;Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea;Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea;Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea;Department of Environmental Health, Korea National Open University, Seoul, South Korea;Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea;Department of Preventive Medicine, Kangwon National University School of Medicine, Kangwon, South Korea;Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea;Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea;

关键词: Breast Cancer;    Breast Cancer Survival;    Nuclear Grade;    Estrogen Receptor Status;    Combine Score;   

DOI  :  10.1186/1471-2407-12-193

 received in 2011-08-21, accepted in 2012-05-14,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundAlthough a number of experimental studies have suggested the role of lipocalin-2 (LCN2) and matrix metalloproteinase-9 (MMP-9) in breast cancer progression, limited numbers of epidemiological studies have examined the relationship between the levels of lipocalin-2 and MMP-9 and breast cancer survival.MethodsPreoperative serum levels of lipocalin-2 and MMP-9 were measured in 303 breast cancer patients and 74 healthy controls recruited between 2004 and 2007. We examined the association between lipocalin-2 and MMP-9 levels and disease-free survival (DFS) using Cox proportional hazard regression model.ResultsThe serum levels of lipocalin-2 and MMP-9 were not significantly different between patients and controls (P > 0.05). Elevated lipocalin-2 and MMP-9 levels were associated with reduced DFS of breast cancer ( Ptrend = 0.029 and Ptrend = 0.063, respectively). When lipocalin-2 and MMP-9 levels were categorized based on the combined risk score, patients with higher levels of both lipocalin-2 and MMP-9 exhibited poor DFS compared to patients with lower levels (Ptrend = 0.004). Furthermore, these effects were profound in patients with BMI less than 25 kg/m2 (adjusted hazard ratio (aHR), 3.17; 95% confidence intervals (CI), 1.66-6.06, Ptrend < 0.001) or lymph-node negative breast cancer (aHR, 5.36; 95% CI, 2.18-13.2, Ptrend < 0.001).ConclusionsOur study suggests that the elevated levels of lipocalin-2 and MMP-9 are associated with reduced breast cancer survival, particularly in patients with lower BMI and lymph-node negative breast cancers.

【 授权许可】

Unknown   
© Sung et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.